Arrow DX, Combining Nanotechnology and Artificial Intelligence to create tests to screen early (NAFLD). S4|Ep4

<p>This week James and Adam speak to Edward Olano Co-Founder & CEO and Murph McKeon CFO of Arrow DX.</p> <p>Arrow Dx is combining Nanotechnology and Artificial Intelligence (AI) to create an inexpensive, sensitive test to screen early for non-alcoholic fatty liver disease (NAFLD).</p> <p>Their aim is to provide physicians with an alternative to a liver biopsy that detects the disease too late. They are working to solve the lack of rapid, reliable, point-of-care, and inexpensive diagnostic devices by bringing faster, inexpensive and mobile testing for many other applications that require rapid response (e.g., epidemic/pandemics, public health crisis, early diagnosis for rising complex non-communicable diseases, testing in emergency rooms).</p> <p>Tune in to hear how Arrow DX was founded and how it’s going.</p>